Eterna Therapeutics Inc
ERNA1.310USD
+0.050+3.97%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
10.28MMarket Cap
0.02P/E TTM
More Details of Eterna Therapeutics Inc Company
Ernexa Therapeutics Inc., formerly Eterna Therapeutics Inc., is a preclinical-stage company. The Company is focused on using cutting-edge gene-editing tools to deliver safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Its Pipeline includes ERNA-101, and ERNA-102. Its core technology utilizes engineer allogenic-induced pluripotent stem cells (iPSCs) to express genes of interest and to efficiently differentiate these cells into mesenchymal stem cells (iMSCs). The Company seeks to capitalize on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), thus unleashing potent anti-cancer immune responses. The Company is focused on developing iPSC-derived iMSC that express critical factors, such as pro-inflammatory cytokines.
Eterna Therapeutics Inc Info
Ticker SymbolERNA
Company nameErnexa Therapeutics Inc
IPO dateAug 29, 1991
CEOLuther (Sanjeev)
Number of employees6
Security typeOrdinary Share
Fiscal year-endAug 29
Address1035 Cambridge Street
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02141
Phone16177986700
Websitehttps://www.ernexatx.com/
Ticker SymbolERNA
IPO dateAug 29, 1991
CEOLuther (Sanjeev)
Company Executives of Eterna Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. James Bristol
Dr. James Bristol
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Sanjeev Luther
Mr. Sanjeev Luther
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Sandra Gurrola
Ms. Sandra Gurrola
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Mr. Peter Cicala
Mr. Peter Cicala
Independent Director
Independent Director
--
--
Dr. Elena Ratner
Dr. Elena Ratner
Independent Director
Independent Director
--
--
Mr. William Wexler
Mr. William Wexler
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. James Bristol
Dr. James Bristol
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Sanjeev Luther
Mr. Sanjeev Luther
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Sandra Gurrola
Ms. Sandra Gurrola
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Mr. Peter Cicala
Mr. Peter Cicala
Independent Director
Independent Director
--
--
Dr. Elena Ratner
Dr. Elena Ratner
Independent Director
Independent Director
--
--
Mr. William Wexler
Mr. William Wexler
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Feb 24
Currency: USDUpdated: Mon, Feb 24
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Subscription revenue
4.88M
84.17%
Other revenue
492.00K
8.48%
Hardware revenue
426.00K
7.34%
By RegionUSD
Name
Revenue
Proportion
United States
5.48M
94.48%
Canada
320.00K
5.52%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Subscription revenue
4.88M
84.17%
Other revenue
492.00K
8.48%
Hardware revenue
426.00K
7.34%
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Cherington (Charles)
35.38%
Freebird Partners LP
9.37%
Regolith Capital Investments LP
6.98%
Corient Private Wealth LLC
5.58%
Halpern (John D)
4.97%
Other
37.71%
Shareholders
Shareholders
Proportion
Cherington (Charles)
35.38%
Freebird Partners LP
9.37%
Regolith Capital Investments LP
6.98%
Corient Private Wealth LLC
5.58%
Halpern (John D)
4.97%
Other
37.71%
Shareholder Types
Shareholders
Proportion
Individual Investor
45.43%
Corporation
17.13%
Investment Advisor/Hedge Fund
5.84%
Investment Advisor
0.67%
Hedge Fund
0.07%
Other
30.86%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
41
60.96K
1.39%
--
2025Q3
41
60.96K
1.43%
+11.15K
2025Q2
43
49.81K
1.46%
-49.41K
2025Q1
43
99.22K
1.95%
+31.31K
2024Q4
43
66.29K
1.50%
+18.87K
2024Q3
58
47.42K
13.15%
+21.41K
2024Q2
75
30.05K
15.12%
-1.27K
2024Q1
113
31.32K
14.73%
-21.80K
2023Q4
118
27.73K
14.65%
+1.57K
2023Q3
132
26.55K
14.69%
-121.00
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Cherington (Charles)
2.78M
36.21%
+1.42M
+104.20%
Jun 09, 2025
Freebird Partners LP
414.10K
5.4%
--
--
Apr 14, 2025
Regolith Capital Investments LP
222.88K
2.91%
--
--
Apr 14, 2025
Corient Private Wealth LLC
17.52K
0.23%
-1.00
-0.01%
Jun 30, 2025
Halpern (John D)
390.45K
5.09%
--
--
Apr 14, 2025
Denny George P Iii
332.71K
4.34%
+3.36K
+1.02%
Apr 14, 2025
IAF, LLC
315.78K
4.12%
+98.75K
+45.50%
Jul 28, 2025
Purchase Capital LLC
66.67K
0.87%
+66.67K
--
Dec 31, 2024
Singer (Nicholas Jason)
54.00K
0.7%
+54.00K
--
Dec 31, 2024
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jun 10, 2025
Merger
15→1
Oct 12, 2022
Merger
20→1
Oct 12, 2022
Merger
20→1
Oct 12, 2022
Merger
20→1
Oct 12, 2022
Merger
20→1
Mar 24, 2021
Merger
2→1
Date
Type
Ratio
Jun 10, 2025
Merger
15→1
Oct 12, 2022
Merger
20→1
Oct 12, 2022
Merger
20→1
Oct 12, 2022
Merger
20→1
Oct 12, 2022
Merger
20→1
Mar 24, 2021
Merger
2→1
Mar 24, 2021
Merger
2→1
Mar 24, 2021
Merger
2→1
Mar 24, 2021
Merger
2→1
FAQs
Who are the top five shareholders of Eterna Therapeutics Inc?
The top five shareholders of Eterna Therapeutics Inc are:
Cherington (Charles) holds 2.78M shares, accounting for 36.21% of the total shares.
Freebird Partners LP holds 414.10K shares, accounting for 5.40% of the total shares.
Regolith Capital Investments LP holds 222.88K shares, accounting for 2.91% of the total shares.
Corient Private Wealth LLC holds 17.52K shares, accounting for 0.23% of the total shares.
Halpern (John D) holds 390.45K shares, accounting for 5.09% of the total shares.
Cherington (Charles) holds 2.78M shares, accounting for 36.21% of the total shares.
Freebird Partners LP holds 414.10K shares, accounting for 5.40% of the total shares.
Regolith Capital Investments LP holds 222.88K shares, accounting for 2.91% of the total shares.
Corient Private Wealth LLC holds 17.52K shares, accounting for 0.23% of the total shares.
Halpern (John D) holds 390.45K shares, accounting for 5.09% of the total shares.
What are the top three shareholder types of Eterna Therapeutics Inc?
The top three shareholder types of Eterna Therapeutics Inc are:
Cherington (Charles)
Freebird Partners LP
Regolith Capital Investments LP
Cherington (Charles)
Freebird Partners LP
Regolith Capital Investments LP
How many institutions hold shares of Eterna Therapeutics Inc (ERNA)?
As of 2025Q4, 41 institutions hold shares of Eterna Therapeutics Inc, with a combined market value of approximately 60.96K, accounting for 1.39% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.03%.
What is the biggest source of revenue for Eterna Therapeutics Inc?
In FY2020, the Subscription revenue business generated the highest revenue for Eterna Therapeutics Inc, amounting to 4.88M and accounting for 84.17% of total revenue.
